Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARTNER neoadjuvant olaparib plus platinum-taxane chemotherapy for triple-negative and/or BRCA-positive breast cancer
ISRCTN58892741Phase 3Active, not recruiting
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- May 2016
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of olaparib, carboplatin and paclitaxel in breast cancer and triple-negative breast cancer (TNBC) (3 arms), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoints: Safety of olaparib added to carboplatin and paclitaxel chemotherapy, Pathological complete response in each research arm and 2 more. Started May 2016; status: active, not recruiting.
02
Drugs
olaparibcarboplatinpaclitaxel
03
Conditions
breast cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ISRCTN58892741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN58892741.